{
    "clinical_study": {
        "@rank": "77233", 
        "arm_group": [
            {
                "arm_group_label": "ASP1517 Low dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP1517 Middle dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP1517 High dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Darbepoetin group", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate safety and efficacy of intermittent oral dosing of ASP1517 in\n      dialysis chronic kidney disease patients with anemia."
        }, 
        "brief_title": "A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Anemia Associated With Chronic Renal Failure (CRF)", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "To evaluate the safety and the dose-response of ASP1517 on hemoglobin (Hb) correction when\n      ASP1517 is applied intermittently in dialysis chronic kidney disease patients with anemia.\n\n      To evaluate the treatment effect on Hb maintenance of ASP1517 administered  intermittently\n      in dialysis chronic kidney disease patients with anemia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who diagnosed as a end-stage kidney disease (ESKD) and are receiving stable\n             chronic maintenance dialysis 3 times per week for \u2265 12 weeks\n\n          -  Patients who are receiving ESA for at least 8 weeks and the dose of ESA is within the\n             dose range of ESA label\n\n          -  Hb value at screening test is \u226510.0 g/dL\n\n          -  Receiving hemodialysis via arteriovenous fistula (AVF) or arteriovenous graft (AVG)\n             or via permanent catheter\n\n          -  Most recent two Hb values before dialysis during washout period must be both <9.5\n             g/dL and one of two Hb values must be tested on first visit of the week\n\n        Exclusion Criteria:\n\n          -  Proliferative retinopathy, age-related macular degeneration, retinal vein occlusion\n             and/or macular edema that is considered to require treatment\n\n          -  Immunological disease with severe inflammation as assessed by the Investigator; even\n             if the inflammation is in remission, the subject is excluded (e.g. lupus\n             erythematosus, rheumatoid arthritis, Sjogren's syndrome, celiac disease, etc)\n\n          -  Having a history of gastric/intestinal resection considered influential on the\n             absorption of the drug in the gastrointestinal tract or active gastroparesis\n\n          -  Uncontrollable hypertension (SBP \u2265160 mmHg and DBP \u2265110 mmHg, before dialysis, at\n             screening test)\n\n          -  Congestive heart failure (NYHA classification III or higher)\n\n          -  Having a history of hospitalization for stroke, myocardial infarction or lung\n             infarction within 24 weeks before 1st registration\n\n          -  Positive for any of the following: human immunodeficiency virus (HIV); hepatitis B\n             surface antigen (HBsAg); or anti-hepatitis C virus antibody (anti-HCV Ab)\n\n          -  Anemia other than anemia due to low/absent renal production of EPO (e.g., iron\n             deficiency anemia, hemolytic anemia, pancytopenia, etc)\n\n          -  Pure red cell aplasia\n\n          -  Using anabolic androgenic steroid, testosterone enanthate or mepitiostan within 6\n             weeks before 1st registration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888445", 
            "org_study_id": "1517-CL-0304"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ASP1517 Low dose group", 
                    "ASP1517 Middle dose group", 
                    "ASP1517 High dose group"
                ], 
                "description": "oral", 
                "intervention_name": "ASP1517", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Darbepoetin group", 
                "description": "iv", 
                "intervention_name": "darbepoetin alfa", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Darbepoetin alfa"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Renal anemia", 
            "Chronic Renal Failure", 
            "ASP1517"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokuriku", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tohoku", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, 4-arm Parallel, Double Blind (Arm 1-3), Open-label (Arm 4), Active-comparator (Darbepoetin Alfa) Study of Intermittent Oral Dosing of ASP1517 in Dialysis Chronic Kidney Disease Patients With Anemia", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of rise in hemoglobin (g/dL/week)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and at Week-6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888445"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Responder is defined as a hemoglobin >10.0 g/dL and an increase in hemoglobin by >1.0 g/dL from baseline", 
                "measure": "Cumulative number of responder patients", 
                "safety_issue": "No", 
                "time_frame": "up to Week-24"
            }, 
            {
                "measure": "Percent of visits at which patients maintain hemoglobin between 10.0-12.0 g/dL after achieving hemoglobin \u226510.0 g/dL for each patients", 
                "safety_issue": "No", 
                "time_frame": "for 28 weeks after dosing"
            }, 
            {
                "measure": "Percent of patients who maintain hemoglobin between 10.0-12.0 g/dL at each visit", 
                "safety_issue": "No", 
                "time_frame": "for 28 weeks after dosing"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}